A practical reference on anti-doping testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-08. Anything still debated is marked as such rather than presented as settled.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
== Hormonal regulation == Insulin is a peptide hormone that is critical for managing the body's metabolism. Insulin is released by the pancreas when blood sugar levels rise, and it has many effects that broadly promote the absorption and storage of sugars, including lipogenesis. Insulin stimulates lipogenesis primarily by activating two enzymatic pathways. Pyruvate dehydrogenase (PDH), converts pyruvate into acetyl-CoA. Acetyl-CoA carboxylase (ACC), converts acetyl-CoA produced by PDH into malonyl-CoA. Malonyl-CoA provides the two-carbon building blocks that are used to create larger fatty acids. Insulin stimulation of lipogenesis also occurs through the promotion of glucose uptake by adipose tissue. The increase in the uptake of glucose can occur through the use of glucose transporters directed to the plasma membrane or through the activation of lipogenic and glycolytic enzymes via covalent modification. The hormone has also been found to have long term effects on lipogenic gene expression. It is hypothesized that this effect occurs through the transcription factor SREBP-1, where the association of insulin and SREBP-1 lead to the gene expression of glucokinase. The interaction of glucose and lipogenic gene expression is assumed to be managed by the increasing concentration of an unknown glucose metabolite through the activity of glucokinase. Another hormone that may affect lipogenesis through the SREBP-1 pathway is leptin. It is involved in the process by limiting fat storage through inhibition of glucose intake and interfering with other adipose metabolic pathways.
== Family sphere == Women in France perform approximately 64% of household labor. Between 1966 and 1986, men's participation in domestic tasks increased slightly but has remained largely unchanged since. Task distribution becomes more unequal in households with two or more children, with men's involvement decreasing by about 10%. A study by INED reports that 30% of men primarily manage household chores; however, this figure does not include the 15% of children involved in family court proceedings following separation, in which fathers may take on increased caregiving and domestic responsibilities. According to a 2010 INSEE study, women spend an average of 3 hours and 26 minutes per day on domestic tasks, compared to 2 hours for men. Child custody is contested in approximately 18% of divorces. In about 90% of cases, custody is awarded to the mother, with few fathers requesting custody. Custody is awarded to fathers in about 8% of cases. Post-divorce, women experience a greater decline in standard of living compared to men. Following separation, approximately one-third of women and one-half of men enter new partnerships. Shared custody arrangements are becoming more common and now account for about 10% of divorce cases.
In January 2023, Germany ambassador to Brazil Heiko Thoms confirmed Chancellor Olaf Scholz would visit Brazil on 30 January. According to a statement, the main subjects to be addressed would be environment (including the re-establishment of the Amazon Fund) and trade between Germany and Brazil. On 30 January, Germany development minister Svenja Schulze announced the country will donate €204 million (US$222 million) to Brazil aiming to help restore farming degraded areas through low-interest rate loans, as well as it will make fresh monetary contributions to the Amazon Fund and provide local aid to Brazilian states in the Amazon region; new sustainable agriculture and green hydrogen projects in Brazil are also being looked upon by the German government, according to Schulze. During the meeting with Scholz, Lula proposed creating a group of countries, including India, Indonesia and China, that would "mediate a peace process" in the Russo-Ukrainian War. In March 2023, Germany's Vice Chancellor Robert Habeck and Agriculture Minister Cem Özdemir, as well as several German business people, attended the German-Brazilian Economic Meeting in Belo Horizonte where they met with vice-president Geraldo Alckmin.
Sources: en.wikipedia.org
== Non-enzymatic transamination == A second type of transamination reaction can be described as a nucleophilic substitution of one amine or amide anion on an amine or ammonium salt. For example, the attack of a primary amine by a primary amide anion can be used to prepare secondary amines:
Ancient philosophers as far back as Thales of Miletus c. 550 BCE had inklings of the conservation of some underlying substance of which everything is made. However, there is no particular reason to identify their theories with what we know today as "mass-energy" (for example, Thales thought it was water). Empedocles (490–430 BCE) wrote that in his universal system, composed of four roots (earth, air, water, fire), "nothing comes to be or perishes"; instead, these elements suffer continual rearrangement. Epicurus (c. 350 BCE) on the other hand believed everything in the universe to be composed of indivisible units of matter—the ancient precursor to 'atoms'—and he too had some idea of the necessity of conservation, stating that "the sum total of things was always such as it is now, and such it will ever remain." In 1605, the Flemish scientist Simon Stevin was able to solve a number of problems in statics based on the principle that perpetual motion was impossible. In 1639, Galileo published his analysis of several situations—including the celebrated "interrupted pendulum"—which can be described (in modern language) as conservatively converting potential energy to kinetic energy and back again. Essentially, he pointed out that the height a moving body rises is equal to the height from which it falls, and used this observation to infer the idea of inertia. The remarkable aspect of this observation is that the height to which a moving body ascends on a frictionless surface does not depend on the shape of the surface.
The specific adaptive immune response regulated by the TH cell depends on its subtype (i.e., T-helper1, T-helper2, T-helper17, and regulatory T-cell), which is distinguished by the types of cytokines they secrete. Regulatory T cells are yet another distinct population of T cells that provide the critical mechanism of tolerance, whereby immune cells are able to distinguish invading cells from "self." This prevents immune cells from inappropriately reacting against one's own cells, known as an autoimmune response. For this reason, these regulatory T cells have also been called "suppressor" T cells. These same regulatory T cells can also be co-opted by cancer cells to prevent the recognition of, and an immune response against, tumor cells.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.